Global attention deficit hyperactivity disorder treatment market is estimated to be valued at US$ 20,183.1 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).
Increasing prevalence of attention deficit hyperactivity disorder is expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) treatment market during the forecast period. For instance, according to the study titled ‘Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder among Adults and Children of Different Racial and Ethnic Groups’ published in the Journal of the American Medical Association (JAMA Network), in September, 2022, the total number of newly diagnosed patients with ADHD were 838,265 between the year 2010 to 2019. While 121,278 individuals were diagnosed at age of 0 to 6 years in Japan.
Furthermore, key companies focusing on research and development for the treatment of attention deficit hyperactivity disorder are expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) treatment market during the forecast period. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a U.S. subsidiary, announced positive top-line results from phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients